Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Phase 1 Completed 47 enrolled Imbrium Therapeutics Purdue Pharma LP · collab

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.

Timeline

Start: 2022-05-26
Primary completion: 2025-01-28
Completion: 2025-01-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunobinop	Small molecule	1 mg	Oral

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Summary

Timeline

Drugs

Indications